|
Nov 3
|
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
|
|
Nov 3
|
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
|
|
Sep 8
|
Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
|
|
Sep 7
|
Oncolytics Biotech® Announces Full Exercise of Over-Allotment Option from Public Offering
|
|
Sep 6
|
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
|
|
Jun 22
|
Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
|
|
Apr 26
|
Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting
|